Evaluation of highly sensitive immunoassay technologies for quantitative measurements of sub-pg/mL levels of cytokines in human serum

David T Yeung(South Australia Pathology), Alvydas Mikulskis(Biogen (United States)), Shobha Purushothama(Biogen (United States)), Douglas Donaldson(Biogen (United States)), Brian Schlain(Biogen (United States)), Shawn Ciotti(Biogen (United States)), Geoffrey Kuesters(Biogen (United States)), Chase Shen(Biogen (United States)), Elham Gharakhani(Biogen (United States))
Journal of Immunological Methods
August 24, 2016
10.1016/j.jim.2016.08.003
Cited by 70

Related Papers

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
|Blood|2013|705
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464
Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study
|Nature Medicine|2020|289
Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease
|Blood|2018|208
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
|Blood|2014|198